Thalidomide for induction of remission in Crohn's disease
Referencias
Additional references
Akobeng AK, Zachos M. Tumor necrosis factor‐alpha antibody for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2003, Issue 4.
Bariol C, Meagher AP, Vickers CR, Byrnes DJ, Edwards PD, Hing M, et al. Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol 2002;17(2):135‐9.
Creed TJ, Probert CS. Review article: steroid resistance in inflammatory bowel disease ‐ mechanisms and therapetic strategies. Aliment Pharmacol Ther 2007;25(2):111‐22.
Deng L, Ding W, Granstein RD. Thalidomide inhibits tumor necrosis factor‐alpha production and antigen presentation by Langerhans cells. J Invest Dermatol 2003;121(5):1060‐5.
Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn's disease: an open‐label trial. Gastroenterology 1999;117(6):1271‐7.
Facchini S, Candusso M, Martelossi S, Liubich M, Panfili E, Ventura A. Efficacy of long‐term treatment with thalidomide in children and young adults with Crohn disease: preliminary results. J Pediatr Gastroenterol Nutr 2001;32(2):178‐81.
Gockel HR, Lügering A, Heidemann J, Schmidt M, Domschke W, Kucharzik T, et al. Thalidomide induces apoptosis in human monocytes by using a cytochrome c‐dependent pathway. J Immunol 2004;172(8):5103‐9.
Gordon JN, Goggin PM. Thalidomide and its derivatives: emerging from the wilderness. Postgrad Med J 2003;79(929):127‐32.
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintennance infliximab for Crohn's disease: the ACCENT 1 randomised trial. Lancet 2002;359(9317):1541‐9.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60.
Higgins JPT, Green S, editors. Assessment of study quality. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane LIbrary, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd., 2005.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996;17(1):1‐12.
Kane S, Stone LJ, Ehrenpreis E. Thalidomide as "salvage" therapy for patients with delayed hypersensitivity response to infliximab: a case series. J Clin Gastroenterol 2002;35(2):149‐50.
Kenet G, Wardi J, Avni Y, Aeed H, Shirin H, Zaidel L, et al. Amelioration of experimental colitis by thalidomide. Isr Med Assoc J 2001;3(9):644‐8.
Lazzerini M, Martelossi S, Marchetti F, Scabar A, Bradaschia F, Ronfani L, et al. Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long‐term results. Aliment Pharmacol Ther 2007;25(4):419‐27.
McBride WG. Thalidomide and congenital abnormalities. Lancet 1961;2:1358.
Moller DR, Wysocka M, Greenlee BM, Ma X, Wahl L, Flockhart DA, et al. Inhibition of IL‐12 production by thalidomide. J Immunol 1997;159(10):5157‐61.
Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumour necrosis factor by enhancing mRNA degradation. J Exp Med 1993;177(6):1675‐80.
Plamondon S, Ng SC, Kamm MA. Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies. Aliment Pharmacol Ther 2007;25(5):557‐67.
Sabate JM, Villarejo J, Lemann M, Bonnet J, Allez M, Modigliani R. An open‐label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. Aliment Pharmacol Ther 2002;16(6):1117‐24.
Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991;173(3):699‐703.
Sands BE, Podolsky DK. New life in a sleeper: thalidomide and Crohn's disease. Gastroenterology 1999;117(6):1485‐8.
Targan SR, Hanauer SB, Van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short‐term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337(15):1029‐35.
Vasiliauskas EA, Kam LY, Abreu‐Martin MT, Hassard PV, Papadakis KA, Yang H, et al. An open‐label pilot study of low‐dose thalidomide in chronically active, steroid‐dependent Crohn's disease. Gastroenterology 1999;117(6):1278‐87.
